Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?

被引：0
|
作者：
Kim, Jong S. [1 ]
机构：
[1] Univ Ulsan, Dept Neurol, Asan Med Ctr, Coll Med, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
来源：
JOURNAL OF STROKE | 2019年 / 21卷 / 03期
关键词：
D O I：
10.5853/jos.2019.02474
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [41] Selection bias in studies of non-vitamin K antagonist oral anticoagulant users with atrial fibrillation
    Hellfritzsch, Maja
    Grove, Erik L.
    Haastrup, Simone B.
    Rasmussen, Lotte
    Pottegard, Anton
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 108 - 108
  • [42] "As Needed" nonvitamin K antagonist oral anticoagulants for infrequent atrial fibrillation episodes following atrial fibrillation ablation guided by diligent pulse monitoring: A feasibility study
    Zado, Erica S.
    Pammer, Monica
    Parham, Tara
    Lin, David
    Frankel, David S.
    Dixit, Sanjay
    Marchlinski, Francis E.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2019, 30 (05) : 631 - 638
  • [43] Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report
    Shen, Long
    Fang, Sha-Sha
    Ge, Heng
    Qiao, Zhi-Qing
    Gu, Zhi-Chun
    MEDICINE, 2018, 97 (18)
  • [44] Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
    Gallu, Mariacarla
    Marrone, Giulia
    Legramante, Jacopo Maria
    De Lorenzo, Antonino
    Di Daniele, Nicola
    Noce, Annalisa
    CARDIOVASCULAR THERAPEUTICS, 2020, 2020
  • [45] Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
    Parasrampuria, Dolly A.
    Weilert, Doris
    Maa, Jen-Fue
    Dishy, Victor
    Kochan, Jarema
    Shi, Minggao
    Brown, Karen S.
    CLINICAL DRUG INVESTIGATION, 2016, 36 (02) : 127 - 136
  • [46] Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
    Dolly A. Parasrampuria
    Doris Weilert
    Jen-Fue Maa
    Victor Dishy
    Jarema Kochan
    Minggao Shi
    Karen S. Brown
    Clinical Drug Investigation, 2016, 36 : 127 - 136
  • [47] Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study
    Gieling, Emilie M.
    van den Ham, Hendrika A.
    van Onzenoort, Hein
    Bos, Jacqueline
    Kramers, Cornelis
    de Boer, Anthonius
    de Vries, Frank
    Burden, Andrea M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (08) : 1844 - 1859
  • [48] The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation
    Chantrarat, Thoranis
    Hauythan, Sakolrat
    IJC HEART & VASCULATURE, 2021, 35
  • [49] Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study
    Zhao, Jiaxi
    Blais, Joseph E.
    Chui, Celine S. L.
    Suh, In-Hye
    Chen, Esa Y. H.
    Seto, Wai-Kay
    Mok, Michael T.
    Yan, Vincent K. C.
    Lau, Wallis C. Y.
    Wong, Ian C. K.
    Chan, Esther W.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (09): : 1513 - 1524
  • [50] Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation
    Asuncion Esteve-Pastor, Maria
    Miguel Rivera-Caravaca, Jose
    Roldan, Vanessa
    Orenes-Pinero, Esteban
    Romiti, Giulio Francesco
    Romanazzi, Imma
    Bai, Ying
    Carmo, Joao
    Proietti, Marco
    Marin, Francisco
    Lip, Gregory Y. H.
    AMERICAN JOURNAL OF CARDIOLOGY, 2018, 122 (05): : 785 - 792
12345